Gabelli analyst Kevin Kedra upgraded Lexicon Pharmaceuticals (NASDAQ: LXRX) from Hold to Buy, price target $3.00.The analyst comments "The Sanofi ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE